Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis
Ensysce Biosciences, Inc. (ENSC) fell 4.11% to USD 0.26 as of July 25, 2026 at 04:20 UTC, according to Nexqual real-time market data.
ENSC last closed at USD 0.27; the session ranged USD 0.26–0.28 on volume of 346,264 shares. Market capitalization is $4.02M, with a 52-week range of USD 0.23–2.75 (NCM). Source: Nexqual, July 25, 2026 at 04:20 UTC.
Key Statistics (as of July 25, 2026 at 04:20 UTC)
| Price | USD 0.26 |
|---|---|
| Change | ▼ 4.11% (down) |
| Previous Close | USD 0.27 |
| Open | USD 0.27 |
| Day Range | USD 0.26 – 0.28 |
| 52-Week Range | USD 0.23 – 2.75 |
| Volume | 346,264 shares |
| Market Cap | $4.02M |
| Exchange | NCM |
Technical Analysis (ENSC)
Nexqual's technical model rates ENSC "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.21 (neutral) |
| vs SMA50 | Below (USD 0.28) |
| MACD | -0 (negative) |
Analyst Ratings (ENSC)
Wall Street analysts rate ENSC "Strong Buy" based on 1 analysts, with a mean price target of USD 16.45 (range USD 16.45–16.45), per Nexqual as of July 25, 2026 at 04:20 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 16.45 |
| High Target | USD 16.45 |
| Low Target | USD 16.45 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (ENSC)
| EPS Estimate | USD -0.5 |
|---|---|
| Revenue Estimate | $1.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.52 vs est -0.73 ▲ beat |
| 2025-12-31 | USD -0.75 vs est -1.26 ▲ beat |
| 2025-09-30 | USD -1.29 vs est -0.93 ▼ miss |
| 2025-06-30 | USD -0.79 vs est -1.28 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financials & Fundamentals (ENSC)
| Total Revenue | $4.71M |
|---|---|
| Revenue Growth (YoY) | -27.20% |
| Gross Margin | -151.46% |
| Operating Margin | -370.68% |
| Profit Margin | -250.36% |
| ROE | -1149.11% |
| Current Ratio | 0.71 |
| Total Cash | $745,482 |
| Total Debt | $245,849 |
| Free Cash Flow | $-5.55M |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financial Health Score (ENSC)
Nexqual rates Ensysce Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:20 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $745K cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -1149%, ROA -218.2% |
Ownership (ENSC)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +3.32% |
| Shares Outstanding | 15.37M |
| Float | 14.68M |
| Short % of Float | +1.19% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Leadership (ENSC)
Ensysce Biosciences, Inc. is led by D. Lynn Kirkpatrick (age 68), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:20 UTC.
| President, CEO & Director | D. Lynn Kirkpatrick (age 68) |
|---|---|
| CFO, Secretary & Treasurer | David C. Humphrey (age 56) |
Major Backers & Investors (ENSC)
Notable institutional backers of Ensysce Biosciences, Inc. include Adage Capital Partners GP L.L.C., Perceptive Advisors Llc, Fidelity, according to Nexqual as of July 25, 2026 at 04:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 0.97% |
| Perceptive Advisors Llc | 0.56% |
| Fidelity | 0.47% |
| Citadel | 0.37% |
| Xtx Topco Ltd | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.48% |
| Vanguard Group | 0.32% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
From Ensysce Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Prescription opioid abuse presents major burdens to society, resulting in significant costs, illnesses, and deaths, many of which we believe could be prevented through the use of our proprietary technologies.
- We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees, and consultants.
- These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third party.
Partnerships
- We also rely on trademarks, trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain our proprietary position.   In August 2020, EBIR entered into a Technology Transfer Agreement with Mucokinetica to acquire its intellectual property and all assets associated with the inhaled nafamostat program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:20 UTC. This page is informational and not investment advice.